Display options
Cite
Tai DJ, Jin WS, Wu CS, et al. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med. 2012;4(2):291-296doi: 10.3892/etm.2012.591.
Tai, D. J., Jin, W. S., Wu, C. S., Si, H. W., Cao, X. D., Guo, A. J., & Chang, J. C. (2012). Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Experimental and therapeutic medicine, 4(2), 291-296. https://doi.org/10.3892/etm.2012.591
Tai, DE-Jun, et al. "Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells." Experimental and therapeutic medicine vol. 4,2 (2012): 291-296. doi: https://doi.org/10.3892/etm.2012.591
Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, Chang JC. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med. 2012 Aug;4(2):291-296. doi: 10.3892/etm.2012.591. Epub 2012 May 24. PMID: 23139717; PMCID: PMC3460287.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2012 Aug;4(2):291-296. doi: 10.3892/etm.2012.591. Epub 2012 May 24.

Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells.

Experimental and therapeutic medicine

DE-Jun Tai, Wen-Sen Jin, Cheng-Si Wu, Hong-Wei Si, Xian-Dong Cao, Ai-Jun Guo, Jia-Cong Chang

Affiliations

  1. Department of General Surgery, The First Affiliated Hospital.

PMID: 23139717 PMCID: PMC3460287 DOI: 10.3892/etm.2012.591

Abstract

Multidrug resistance (MDR) to chemotherapeutic agents is a major obstacle for the treatment of various types of cancers. The exact mechanism of MDR has not yet been fully clarified, although it has been frequently associated with the variation of intracellular redox status. The levels of intracellular glutathione (GSH) are considered to play a vital role in the regulation of the intracellular redox status. In our study, we investigated the effects of buthionine sulfoximine (BSO), an inhibitor of GSH biosynthesis, and NAC, a cysteine source for GSH synthesis, on sensitive gastric adenocarcinoma cells (SGC7901) and cisplatin-resistant SGC7901/DDP cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The two cell lines were pretreated with various non-toxic concentrations of BSO for 24 h and combined with fluorouracil (5-FU) or mitomycin (MMC) in the presence or absence of NAC before culturing further. After various treatments, the IC(50) values of MMC and 5-FU were calculated and intracellular GSH levels were measured using the glutathione reductase/5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) recycling assay without anticancer drug stimulation under the same microenvironments. The study demonstrated that BSO increased the sensitivity of the cells to chemotherapeutics while NAC exhibited the reverse effect, particularly in drug-resistant cells. It is, therefore, possible that changes in intracellular GSH levels affect the chemosensitivity of the resistant cells to a greater extent than that of their parent cells. This study indicates that variation in the intracellular redox status may be closely correlated with MDR and may provide a valuable basic strategy for anticancer therapy.

References

  1. Eur J Clin Invest. 2004 Oct;34(10):683-9 - PubMed
  2. Neoplasma. 1994;41(3):163-9 - PubMed
  3. Cell Mol Life Sci. 2001 Jun;58(7):931-59 - PubMed
  4. Leukemia. 2000 Mar;14(3):467-73 - PubMed
  5. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5431-6 - PubMed
  6. N Engl J Med. 2001 Sep 6;345(10):725-30 - PubMed
  7. Met Based Drugs. 2010;2010: - PubMed
  8. Cancer Cell Int. 2005 Jul 24;5(1):22 - PubMed
  9. J Appl Toxicol. 2011 Oct;31(7):618-25 - PubMed
  10. Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 - PubMed
  11. Oncogene. 2003 Oct 20;22(47):7265-79 - PubMed
  12. Anticancer Drug Des. 1999 Apr;14(2):143-51 - PubMed
  13. Acta Pharmacol Sin. 2005 Aug;26(8):1009-16 - PubMed
  14. Ann Oncol. 1997 Feb;8(2):163-8 - PubMed
  15. Eur J Cancer. 2000 Feb;36(3):428-34 - PubMed
  16. Ann Oncol. 2003;14 Suppl 2:ii31-6 - PubMed
  17. Clin Cancer Res. 2004 May 15;10(10):3237-48 - PubMed
  18. Pharmacol Rev. 1995 Jun;47(2):271-330 - PubMed
  19. Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 - PubMed
  20. Curr Treat Options Oncol. 2007 Feb;8(1):38-46 - PubMed
  21. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 - PubMed
  22. Int J Mol Med. 2010 Apr;25(4):657-62 - PubMed
  23. Cancer Res. 1992 Dec 1;52(23):6666-70 - PubMed
  24. Cancer Treat Rev. 1998 Apr;24(2):113-8 - PubMed
  25. Cancer Biol Ther. 2006 Jun;5(6):569-72 - PubMed
  26. Biochim Biophys Acta. 1999 Dec 6;1461(2):359-76 - PubMed
  27. Cell Death Differ. 2009 Oct;16(10):1303-14 - PubMed
  28. Gynecol Oncol. 2009 Jan;112(1):275-81 - PubMed
  29. BMC Cancer. 2002 Dec 26;2:37 - PubMed
  30. Biochemistry (Mosc). 2000 Jan;65(1):95-106 - PubMed
  31. Pharmacol Ther. 2000 Mar;85(3):217-29 - PubMed
  32. Clin Cancer Res. 2008 May 1;14(9):2519-26 - PubMed
  33. Eur J Cancer. 1996 Jun;32A(6):927-44 - PubMed
  34. Nat Rev Drug Discov. 2005 Apr;4(4):307-20 - PubMed
  35. Biochem Biophys Res Commun. 1999 Feb 24;255(3):618-24 - PubMed
  36. Brain Res Brain Res Rev. 2001 Apr;35(2):161-204 - PubMed
  37. Cancer Sci. 2004 Aug;95(8):679-84 - PubMed
  38. World J Gastroenterol. 2002 Dec;8(6):1029-34 - PubMed
  39. Cancer Lett. 2005 Jan 20;217(2):181-90 - PubMed
  40. Cancer Lett. 1998 Jul 3;129(1):69-76 - PubMed
  41. Jpn J Cancer Res. 1996 Dec;87(12):1263-70 - PubMed
  42. N Engl J Med. 2006 Jul 6;355(1):11-20 - PubMed
  43. Environ Toxicol Pharmacol. 2009 Nov;28(3):357-62 - PubMed
  44. Cancer Biol Ther. 2006 Mar;5(3):261-6 - PubMed
  45. Int Rev Cytol. 1978;54:109-60 - PubMed
  46. Biochem Biophys Res Commun. 1997 Nov 26;240(3):606-11 - PubMed
  47. Trends Pharmacol Sci. 2008 Oct;29(10):515-9 - PubMed
  48. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13033-7 - PubMed
  49. Int J Cancer. 1999 Dec 10;83(6):870-873 - PubMed
  50. Clin Cancer Res. 2001 Mar;7(3):454-61 - PubMed
  51. J Exp Clin Cancer Res. 2011 May 19;30:61 - PubMed

Publication Types